787585-27-7

Basic information

• Product Name: Oxirane, [[(1R)-1-(2-bromophenyl)ethoxy]methyl]-, (2R)-
• CAS NO: 787585-27-7
• Molecular Formula: C11H13BrO2
• Molecular Weight: 257.127
• Mol File: 787585-27-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Oxirane, [[(1R)-1-(2-bromophenyl)ethoxy]methyl]-, (2R)-(CAS DataBase Reference)
• NIST Chemistry Reference: Oxirane, [[(1R)-1-(2-bromophenyl)ethoxy]methyl]-, (2R)-(787585-27-7)
• EPA Substance Registry System: Oxirane, [[(1R)-1-(2-bromophenyl)ethoxy]methyl]-, (2R)-(787585-27-7)

Safety Data

• Hazardous Substances Data: 787585-27-7(Hazardous Substances Data)

Upstream product

• 113826-06-5 (R)-glycidyl tosylate 
• 5411-56-3 (1R)-1-(2-bromophenyl)ethan-1-ol 
• 460048-01-5 R-(-)-glycidyl 3-nitrobenzenesulfonate 
• 115314-14-2 (R)-glycidyl nosylate 

Downstream Products

• 804555-44-0 methyl 3-[2-[(1R)-1-(((2R)-oxiranyl)methoxy)ethyl)phenyl]propionate 
• 1260380-28-6 C₂₇H₃₃NO₄ 
• 1260380-43-5 C₂₉H₃₇NO₄ 
• 1260380-32-2 C₂₈H₃₁ClFNO₄ 
• 787583-71-5 Encaleret 
• 1260380-31-1 C₃₂H₃₅NO₄ 
• 1260380-44-6 C₃₃H₃₇NO₄ 
• 1232829-32-1 methyl (3E)-4-(2-{(1R)-1-[(2R)-oxiran-2-ylmethoxy]ethyl}phenyl)but-3-enoate 
• 804555-46-2 methyl 6-[2-[(1R)-1-(((2R)-oxiranyl)methoxy)ethyl]phenyl]hexanoate 
• 1232828-91-9 methyl (2E)-3-(2-{(1R)-1-[(2R)-oxiran-2-yl methoxy]ethyl}phenyl)prop-2-enoate 

Relevant articles and documents

Discovery of a potent and short-acting oral calcilytic with a pulsatile secretion of parathyroid hormone

Short-acting oral calcilytics, calcium-sensing receptor (CaSR) antagonists, have been considered as alternatives for parathyroid hormone (PTH), an injectable bone anabolic drug used in the treatment of osteoporosis. Previously, we identified aminopropandi

1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists

The present invention is directed to novel 1,1 -(dimethyl-ethylamino)-2- hydroxy-propoxy]-ethyl}-3-methyl-biphenyl-4-carboxylic acid derivatives and pharmaceutically acceptable salts thereof of structural formula I wherein the variable R1 is as described herein. Also provided are pharmaceutical compositions comprising the compounds of formula I as well as methods of treatment employing compounds of formula I to treat a disease or disorder characterized by abnormal bone or mineral homeostasis such as hypoparathyroidism, osteoporosis, osteopenia, periodontal disease, Paget's disease, bone fracture, osteoarthritis, rheumatoid arthritis, and humoral hypercalcemia of malignancy.

CaSR antagonist

A compound represented by the following formula (1), a pharmaceutically acceptable salt thereof or an optically active form thereof: wherein each symbol is as defined in the specification. A compound having a calcium-sensing receptor antagonistic action, a pharmaceutical composition comprising the compound, particularly a calcium receptor antagonist and a therapeutic drug for osteoporosis are provided.